← 產業報告目錄
Small Molecule Innovator CDMO Market Size, Share & Trends Analysis Report by Product (Small Molecule API, Small Molecule Drug Product), By Stage Type (Preclinical, Phase I, Phase II, Phase III, and Commercial), By Customer Type (Pharmaceutical and Biotechnology), By Therapeutic Area, Region And Segment Forecasts, 2025-2034
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-01-10頁數 180報告編號 INSIGHTACE-19b3abfa5c
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
With a 2024 valuation of USD 51.2 Billion, the global Small Molecule Innovator CDMO Market is anticipated to expand to USD 93.6 Billion by 2034, demonstrating a CAGR of 6.3% during the 2025–2034 forecast window.
At its core, Small Molecule Innovator CDMO pertains to The small molecule innovator CDMO (Contract Development and Manufacture Organization) market represents a subset of the pharmaceutical business that provides contract services for small molecule drug developm. Stakeholders across the healthcare landscape are expandingly turning to these solutions to meet contemporary demands.
Several factors contribute to this trajectory, including heightened interest in next-generation products, expanding applications across diverse end-use sectors, and supportive government initiatives.
Segmental analysis reveals differentiated growth across product categories, applications, and geographical regions, with certain niches demonstrating above-average expansion potential.
Geographically, North America maintains a leading position owing to advanced infrastructure, high R&D expenditure, and a well-established regulatory environment. Meanwhile, Asia-Pacific is emerging as the fastest-growing region, supported by rapid industrialization and expanding end-user bases.
Industry participants are deploying a range of strategies—including partnerships, mergers, technological investments, and portfolio diversification—to consolidate their market standing.
Through rigorous analysis of market trends, growth catalysts, restraints, and opportunities, this study offers valuable perspectives for companies, investors, and policymakers navigating this evolving landscape.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Small Molecule Innovator CDMO Market Snapshot
Chapter 4. Global Small Molecule Innovator CDMO Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. COVID-19 Impact Analysis
Chapter 5. Market Segmentation 1: By Product Estimates & Trend Analysis
5.1. By Product & Market Share, 2024-2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Product:
5.2.1. Small Molecule API
5.2.2. Small Molecule Drug Product
5.2.2.1. Oral solid Dose
5.2.2.2. Semi-Solid Dose
5.2.2.3. Liquid Dose
5.2.2.4. Others
Chapter 6. Market Segmentation 2: By Stage Type Estimates & Trend Analysis
6.1. By Product & Market Share, 2024-2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Stage Type:
6.2.1. Preclinical
6.2.2. Clinical
6.2.2.1. Phase I
6.2.2.1.1. Small
6.2.2.1.2. Medium
6.2.2.1.3. Large
6.2.2.2. Phase II
6.2.2.2.1. Small
6.2.2.2.2. Medium
6.2.2.2.3. Large
6.2.2.3. Phase III
6.2.2.3.1. Small
6.2.2.3.2. Medium
6.2.2.3.3. Large
6.2.3. Commercial
Chapter 7. Market Segmentation 3: By Customer Type Estimates & Trend Analysis
7.1. By Product & Market Share, 2024-2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Customer Type:
7.2.1. Pharmaceutical
7.2.1.1. Small
7.2.1.2. Medium
7.2.1.3. Large
7.2.2. Biotechnology
Chapter 8. Market Segmentation 4: By Therapeutic Area Estimates & Trend Analysis
8.1. By Product & Market Share, 2024-2034
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Therapeutic Area:
8.2.1. Cardiovascular disease
8.2.2. Oncology
8.2.3. Respiratory disorders
8.2.4. Neurology
8.2.5. Metabolic disorders
8.2.6. Infectious disease
8.2.7. Others
Chapter 9. Small Molecule Innovator CDMO Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. North America Small Molecule Innovator CDMO Market revenue (US$ Million) estimates and forecasts By Product, 2021-2034
9.1.2. North America Small Molecule Innovator CDMO Market revenue (US$ Million) estimates and forecasts By Stage Type, 2021-2034
9.1.3. North America Small Molecule Innovator CDMO Market revenue (US$ Million) estimates and forecasts By Customer Type, 2021-2034
9.1.4. North America Small Molecule Innovator CDMO Market revenue (US$ Million) estimates and forecasts By, Therapeutic Area2021-2034
9.1.5. North America Small Molecule Innovator CDMO Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
9.1.5.1. U.S.
9.1.5.2. Canada
9.2. Europe
9.2.1. Europe Small Molecule Innovator CDMO Market revenue (US$ Million) by Product, 2021-2034
9.2.2. Europe Small Molecule Innovator CDMO Market revenue (US$ Million) estimates and forecasts By Stage Type, 2021-2034
9.2.3. Europe Small Molecule Innovator CDMO Market revenue (US$ Million) estimates and forecasts By Hardware 2021-2034
9.2.4. Europe Small Molecule Innovator CDMO Market revenue (US$ Million) estimates and forecasts By Therapeutic Area,2021-2034
9.2.5. Europe Small Molecule Innovator CDMO Market revenue (US$ Million) by country, 2021-2034
9.2.5.1. Germany
9.2.5.2. Poland
9.2.5.3. France
9.2.5.4. Italy
9.2.5.5. Spain
9.2.5.6. UK
9.2.5.7. Rest of Europe
9.3. Asia Pacific
9.3.1. Asia Pacific Small Molecule Innovator CDMO Market revenue (US$ Million) by Product, 2021-2034
9.3.2. Asia Pacific Small Molecule Innovator CDMO Market revenue (US$ Million) estimates and forecasts By Stage Type, 2021-2034
9.3.3. Asia Pacific Small Molecule Innovator CDMO Market revenue (US$ Million) estimates and forecasts By Customer Type, 2021-2034
9.3.4. Asia Pacific Small Molecule Innovator CDMO Market revenue (US$ Million) estimates and forecasts By Therapeutic Area, 2021-20
9.3.5. Asia Pacific Small Molecule Innovator CDMO Market revenue (US$ Million) by country, 2021-2034
9.3.5.1. China
9.3.5.2. India
9.3.5.3. Japan
9.3.5.4. Australia
9.3.5.5. Rest of Asia Pacific
9.4. Latin America
9.4.1. Latin America Small Molecule Innovator CDMO Market revenue (US$ Million) by By Product, 2021-2034
9.4.2. Latin America Small Molecule Innovator CDMO Market revenue (US$ Million) estimates and forecasts By Stage Type, 2021-2034
9.4.3. Latin America Small Molecule Innovator CDMO Market revenue (US$ Million) estimates and forecasts By Capping Method, 2021-2034
9.4.4. Latin America Small Molecule Innovator CDMO Market revenue (US$ Million) estimates and forecasts By Therapeutic Area, 2021-2034
9.4.5. Latin America Small Molecule Innovator CDMO Market revenue (US$ Million) by country, (US$ Million) 2021-2034
9.4.5.1. Brazil
9.4.5.2. Rest of Latin America
9.5. Middle East & Africa
9.5.1. Middle East & Africa Small Molecule Innovator CDMO Market revenue (US$ Million) by Product, (US$ Million)
9.5.2. Middle East & Africa Small Molecule Innovator CDMO Market revenue (US$ Million) estimates and forecasts By Stage Type, 2021-2034
9.5.3. Middle East & Africa Small Molecule Innovator CDMO Market revenue (US$ Million) estimates and forecasts By Customer Type, 2021-2034
9.5.4. Middle East & Africa Small Molecule Innovator CDMO Market revenue (US$ Million) estimates and forecasts By Therapeutic Area, 2021-2034
9.5.5. Middle East & Africa Small Molecule Innovator CDMO Market revenue (US$ Million) by country, (US$ Million) 2021-2034
9.5.5.1. South Africa
9.5.5.2. GCC Countries
9.5.5.3. Rest of MEA
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1 Cambrex Corporation
10.2.2 Bellen Chemistry
10.2.3 Zhejiang LangHua Pharmaceutical Co., LTD.
10.2.4 Raffles PharmaTech Co., Ltd
10.2.5 Shanghai Mathcon Pharmaceutical Co., LTD
10.2.6 Shanghai SynTheAll Pharmaceutical Co., Ltd.
10.2.7 Wisdom Pharmaceutical Co., Ltd.
10.2.8 Gear Pharma
10.2.9 Hangzhou Aoya Biotechnology Co., Ltd.
10.2.10 Desano Inc.
10.2.11 Redhill Biopharma Ltd
10.2.12 Shanghai Chemspec Corporation
10.2.13 Zhejiang Chetou Pharmaceutical Co., Ltd
10.2.14 Oncomed manufacturing a.s.
10.2.15 Piramal Pharma Solutions
10.2.16 CordenPharma International
10.2.17 Wuxi AppTec
10.2.18 Cambrex Corporation
10.2.19 Recipharm AB
10.2.20 Pantheon (Thermo Fisher Scientific)
10.2.21 Lonza
10.2.22 Catalent Inc.
10.2.23 Siegfried Holding AG
10.2.24 Boehringer Ingelheim
10.2.25 Labcorp Drug Development
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們